Published in final edited form as:

Neurobiol Aging. 2019 February ; 74: 171–181. doi:10.1016/j.neurobiolaging.2018.10.013.

In-Vivo hippocampal subfield shape related to TDP-43, amyloid beta, and tau pathologies

Veronika Hanco^a, Alexandra C Apple^a, Kathryn I Alpert^a, Kristen N Warren^a, Julie A Schneider^b, Konstantinos Arfanakis^{b,c}, David A Bennett^b, and Lei Wang^{a,d}

^aDepartment of Psychiatry and Behavioral Sciences, Northwestern University Feinberg School of Medicine

^bRush Alzheimer's Disease Center, Rush University Medical Center

^cDepartment of Biomedical Engineering, Illinois Institute of Technology

^dDepartment of Radiology, Northwestern University Feinberg School of Medicine

Abstract

Despite advances in the development of biomarkers for Alzheimer's disease (AD), accurate ante-mortem diagnosis remains challenging since a variety of neuropathologic disease states can coexist and contribute to the AD dementia syndrome. Here we report a neuroimaging study correlating hippocampal deformity with regional AD and TDP-43 pathology burden. We utilized hippocampal shape analysis of ante-mortem T1-weighted structural MRI images of 42 participants from two longitudinal cohort studies conducted by the Rush Alzheimer's Disease Center. Surfaces were generated for the whole hippocampus and zones approximating underlying subfields using a previously developed automated image segmentation pipeline. Multiple linear regression models were constructed to correlate shape with pathology measures while accounting for covariates, with relationships mapped out onto hippocampal surface locations. A significant relationship existed between higher PHF-tau burden and inward hippocampal shape deformity in zones approximating CA1 and subiculum which persisted after accounting for coexisting pathologies. No significant patterns of inward surface deformity were associated with amyloid-beta or TDP-43 after including

Correspondence: Lei Wang, Northwestern University Feinberg School of Medicine, Department of Psychiatry and Behavioral Sciences, 710 N. Lake Shore Drive, Abbott Hall 1322, Chicago, IL 60611, Tel. office 312-503-3983, Fax: 312-503-0527, leiwang1@northwestern.edu.

Verification:

1. Authors disclosure:

(a) There are no actual or potential conflicts of interest.

(b) No author's institution has contracts relating to this research through which it or any other organization may stand to gain financially now or in the future.

(c) No other agreements of authors or their institutions that could be seen as involving a financial interest in this work.

2. No sources of financial support related to the manuscript being submitted.

3. We verify that the data contained in the manuscript being submitted have not been previously published, have not been submitted elsewhere and will not be submitted elsewhere while under consideration at *Neurobiology of Aging*.

4. We verify that appropriate approval and procedures were used concerning human subjects and animals.

5. We verify that all authors have reviewed the contents of the manuscript being submitted, approved of its contents and validated the accuracy of the data.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

covariates. Our findings indicate that hippocampal shape deformity measures in surface zones approximating CA1 may represent a biomarker for postmortem AD pathology.

Keywords

Alzheimer disease; TDP-43; neuroimaging; hippocampus; biomarker

1. Introduction

As the population of the United States continues to age, dementia remains a significant contributor to both mortality and healthcare costs (Hurd et al. 2013, Tinetti et al. 2012). While Alzheimer disease (AD) related pathology is the most common, clinical-pathologic studies have shown that non-Alzheimer's neurodegenerative pathologies such as vascular disease, alpha-synuclein, and transactive response DNA-binding protein of 43kDA (TDP-43) proteinopathy are much more common than was previously realized (Schneider et al. 2007a, Kovacs et al. 2013, Toledo et al. 2013) and that mixed pathologies dominate the pathologic landscape in older persons. In recent years, TDP-43 – an RNA/DNA binding protein found to be a major component of neuronal inclusions in amyotrophic lateral sclerosis (ALS) and also in a subset of frontotemporal lobar degeneration (FTLD) cases – has been found to be associated with tauopathies such as AD pathology as well (Chang et al. 2016, Wilson et al. 2011). Given that so many different underlying disease processes can contribute to the AD dementia syndrome, the success of any future therapeutic treatments for neurodegenerative disorders will largely depend on the ability to achieve an early and accurate ante-mortem diagnosis.

Unfortunately, the ability to accurately identify each of the different types of neuropathologies that contribute to AD dementia remains an unmet challenge (Karageorgiou and Miller 2014, Rohrer and Rosen 2013). Furthermore, it is now commonly accepted that AD and related neurodegenerative conditions have a long prodromal period during which pathologic features are developing while persons remain asymptomatic (de Flores et al. 2015). Over the last decade, significant progress has been made in the discovery of molecularly specific biomarkers for AD, including cerebrospinal fluid markers for tau and amyloid-beta as well as imaging biomarkers using PET scanning (Scheltens et al. 2016, Frisoni et al. 2010). Advances in the development of radioactive ligands for amyloid-beta (Jansen et al. 2015, Ossenkoppele et al. 2015, Clark et al. 2012) and to some extent tau (Villemagne et al. 2015) bring the possibility of imaging specific disease processes in-vivo. However, no reliable imaging tracers for non-AD pathologies such as alpha-synuclein, hippocampal sclerosis, or TDP-43 have been found to date.

Multiple groups have employed structural MRI to classify different types of dementia based on patterns of atrophy, but few can confirm their results with pathological evidence (Vemuri et al. 2010, Kim et al. 2014, Li et al. 2016, Mak et al. 2016, Chow et al. 2012, Davatzikos 2008, Du 2007, Thaker 2017). This is problematic since a mixture of multiple neuropathologies can coexist in the brains of older adults (Schneider et al. 2007a). Several investigators have directly correlated spatial brain atrophy patterns measured from

postmortem *ex-vivo* MRI with underlying neuropathologic disease burden obtained from autopsy data in the same subjects (Kotrotsou et al. 2015, Dawe et al. 2011). In Kotrotsou et al (2015), the authors performed *ex-vivo* MRI on a relatively large sample of subjects from two longitudinal cohort studies who underwent autopsy and found a significant correlation between AD pathology and regional brain volumes. Although post-mortem MRI techniques can enhance autopsy studies by providing fundamental insight into the connection between imaging and immunohistochemical findings, the challenge of finding useful *in-vivo* imaging markers of neuropathology remains. Investigators are beginning to address this problem by using antemortem *in-vivo* MRI to correlate spatial brain atrophy patterns with underlying neuropathologic disease burden (Raman et al. 2014, Kantarci et al. 2012).

In the present study, we explored the utility of high-dimensional analysis of *in-vivo* hippocampal shape based on structural MRI as biomarkers for underlying pathological disease states. Relative to other biomarkers, structural MRI is minimally invasive and an accepted component of the diagnostic workup for dementia (Knopman et al. 2001). We chose specifically to focus on the hippocampal, as this region is the earliest to show signs of atrophy in AD and is vulnerable to other pathological disease processes as well (de Flores et al. 2015), and shape information has been shown to be more sensitive to disease progression than volume when predicting dementia onset (Csernansky et al., 2005). Hippocampal subfield analysis has also been shown to have higher diagnostic value in preclinical stages of disease than whole hippocampal volumetry (Mueller et al. 2010). While our goal was to identify relationships between hippocampal shape patterns and specific neuropathology burdens, we also utilized our surface-based zones (Csernansky et al. 2005, Wang et al. 2003) to help interpret our patterns in relationship to underlying subfields. Our group had previously demonstrated that subjects with early stage AD-type dementia showed a distinct hippocampal shape deformity that involved the CA1 and subiculum subfields compared with non-demented controls (Csernansky et al. 2004; Wang et al. 2006; Wang et al. 2009). We now applied a similar method to correlate ante-mortem measures of hippocampal shape with relative amounts of AD- and TDP-43-related disease burden in the postmortem brain. Rather than limiting our study to individuals with clinically apparent AD diagnoses, we chose instead to focus on a community-based cohort of elderly adults with a mixed clinical profile (Bennett et al. 2012a, Bennett et al. 2012b). The rationale for this was two-fold. First, this avoided the need to make any *a priori* assumptions regarding pathology. Second, we hoped to capture the effect of neuropathology on hippocampal deformity at earlier, pre-clinical stages of disease. We hypothesized that each of the three abnormal protein aggregates we examined (i.e. phosphorylated tau, amyloid-beta, and TDP-43) would correlate with distinct spatial patterns of hippocampal atrophy.

2. Methods and materials

2.1. Study population

Participants from two longitudinal cohort studies at the Rush Alzheimer's Disease Center were included in this work. Specifically, subjects came from either the Religious Orders Study or the Rush Memory and Aging Project (Bennett et al. 2012a, Bennett et al. 2012b). Participants in the Religious Orders Study consisted of older Catholic nuns, priests, or

brothers from across the United States, while participants in the Rush Memory and Aging Project were older lay persons from across northeastern Illinois. The sole inclusion criteria was agreeing to sign an informed consent agreeing to annual clinical evaluation, biennial MRI and organ donation, and agreeing to sign an Anatomical Gift Act. Both studies were approved by the institutional review board at Rush University Medical Center. All participants underwent annual detailed clinical evaluations, and signed an informed consent and an anatomical gift act for brain donation upon death. Participants underwent a detailed evaluation that included medical history, neurologic examination and 21 cognitive performance tests, 19 of which were in common. Clinical diagnostic classification of dementia, Alzheimer's dementia, and mild cognitive impairment (MCI) were made in a multi-step process by a neuropsychologist and clinician as previously described (Bennett, 2002; Bennett 2006). Diagnoses of dementia and Alzheimer's dementia followed the recommendations of the NINDS/ADRDA criteria (McKhann 1984) and were consistent the revised criteria (McKhann et al. 2011). MCI referred to the presence of cognitive impairment in the absence of dementia and were consistent with the most recent criteria (Albert et al. 2011). The MMSE was use for descriptive purposes. Seventeen tests were used to summarize five cognitive domains including episodic memory, working memory, semantic memory, processing speed, and visuospatial ability as well as a global cognitive measure based on all 17 tests. Subjects who had undergone *in-vivo* structural MRI prior to death whose autopsy findings showed any sign of AD or TDP-43 pathology were included in this study.

2.2. Neuropathologic evaluation

Detailed procedures for postmortem brain tissue preparation and neuropathology analyses are described in previous publications (Arvanitakis et al., 2011, Bennett et al., 2004, Dawe et al., 2011, Kotrotsou et al. 2015, Schneider et al., 2004, Schneider et al., 2007a, Schneider et al., 2012). Here we provide a summary of the procedures and neuropathological measures used in this work.

At autopsy, brains of the deceased subjects were removed, divided into left and right hemispheres, and one hemisphere was immersion fixed in 4% phosphate-buffered paraformaldehyde solution. The fixed hemisphere was cut into 1 cm-thick coronal slabs for subsequent tissue dissection, pathological diagnosis and macroscopic and microscopic pathology procedures focused on the diagnosis and measurement of indices of AD and related disorders. Each case was reviewed by a board-certified neuropathologist who was blinded to age and clinical diagnoses, and assigned a modified NIA-Reagan score for presence and severity of AD neuropathologic changes based on consensus recommendations for postmortem diagnosis of AD, which relied on neurofibrillary tangles and plaques (Bennett et al. 2006, Consensus recommendations 1997). See Kotrotsou et al. (2015).

Amyloid-beta-immunoreactive plaques were assessed in eight brain regions: hippocampus CA1 and subiculum, entorhinal cortex, inferior temporal cortex, anterior cingulate cortex, angular gyrus, calcarine cortex, midfrontal gyrus, and superior frontal gyrus. Sections were stained with a monoclonal antibody (1:50; amyloid-beta, Clone 6F/3D, Dako) with diaminobenzidine as the reporter, with 2.5% nickel sulfate to enhance contrast. Computer-

assisted sampling and image analysis were used to quantify the average percent area occupied by amyloid-beta within each cortical region. A global composite measure of amyloid-beta burden was created by averaging the regional measures, and used in our statistical analyses as the primary neuropathological variable. See Bennett et al. (2004).

Tau-immunoreactive neurofibrillary tangles were assessed in the same eight regions examined for amyloid-beta. Sections were stained with an anti-paired helical filaments-tau (PHF-tau) antibody clone AT8 (ThermoScientific; 1:2000). Computer-assisted sampling was used to quantify the density of PHF-tau positive neuronal neurofibrillary tangles in each region (Wilson et al., 2013). A global composite measure of PHF-tau density was created by averaging the regional measures, and used in our statistical analyses as the primary neuropathological variable. See Bennett et al. (2004).

TDP-43 pathology was assessed in six brain regions: amygdala, hippocampus CA1, hippocampus dentate gyrus, entorhinal cortex, midfrontal cortex, and middle temporal cortex. Sections were stained with monoclonal antibodies to phosphorylated TDP-43 (pS409/410; 1:100). Each region of interest was rated on a 6-point scale based on the number of inclusions in a 0.25-mm² area of greatest density within that region (none, sparse [1-2 inclusions], sparse to moderate [3-5 inclusions], moderate [6-12 inclusions], moderate to severe [13-19 inclusions], and severe [20 or more inclusions]). A global composite measure of TDP-43 inclusions was created by summing the regional inclusions, and used in our statistical analyses as the primary neuropathological variable. See Wilson et al. (2013).

Hippocampal sclerosis (Schneider et al. 2009), Lewy bodies, gross infarcts, atherosclerosis, arteriolosclerosis, and cerebral amyloid angiopathy were measured and used as covariates in our study. Greater details of the assessments of these neuropathologies can be found in the publications cited herein. Lewy bodies were assessed in the substantia nigra, entorhinal cortex, anterior cingulate cortex, midfrontal cortex, superior or middle temporal cortex, and inferior parietal cortex, using a monoclonal antibody to alpha-synuclein (Zymed LB 509; 1:50) (Buchman et al., 2017; Kapasi et al., 2017). Gross and microscopic infarcts were identified as previously described (Schneider et al. 2004, Arvanitakis et al. 2011) and were scored as none, one, or more than one (Schneider et al. 2007b). Atherosclerosis was assessed based on the extent of vascular involvement at the circle of Willis, while arteriolosclerosis was determined by the severity of wall thickening and luminal occlusion of small arterioles in sections of the anterior basal ganglia (Arvanitakis et al., 2017; Kotrotsou et al. 2015). Cerebral amyloid angiopathy (CAA) was assessed on paraffin-embedded sections from the angular gyrus, midfrontal, temporal, and calcarine cortices, as previously described (Boyle et al., 2015; Kotrotsou et al. 2015). Atherosclerosis, arteriosclerosis, and CAA were all rated on a 4 point scale from none to severe (Arvanitakis et al., 2017).

2.3. Image acquisition, segmentation, and processing: hippocampal surface + subfield zone generation

High-resolution T1-weighted anatomical data were obtained antemortem on a 1.5 Tesla GE (General Electric, Waukesha, WI) MRI scanner, using a 3D magnetization-prepared rapid acquisition gradient echo (MPRAGE) sequence with the following parameters: TE=2.8ms, TR=6.3ms, FOV=24cm × 24cm, flip angle = 8 degrees, 160 slices, 1mm slice thickness,

224×192 image matrix reconstructed to 256×256, 2 repetitions (Bennett et al. 2013, Stoub et al. 2005). Hippocampal segmentations were generated using a previously developed automated image processing pipeline, multi-atlas Freesurfer-Initiated Large Deformation Diffeomorphic Metric Mapping (FS-LDDMM) (Khan et al. 2008, Wang et al. 2009, Christensen et al. 2015). For this analysis, a multi-atlas library consisting of 74 atlas scans with previously delineated expert manual segmentations of the hippocampus was used. In each of the 74 FS-LDDMM maps, Freesurfer (Fischl et al. 2002) was used for initial alignment of subject images to each atlas image, followed by large diffeomorphic metric mapping (LDDMM) (Beg et al. 2005) to generate hippocampal segmentations from each atlas based on high-dimensional transformations computed between the atlas and the subject. A final segmentation was generated for each subject by voxel averaging the segmentations, and a surface with corresponding vertices across all subjects were propagated from a previously developed template (Csernansky et al. 2004). Visual inspection is performed after mapping to ensure data quality.

2.4. Deformation and statistical analysis on surface

To quantify hippocampal surface shape deformity, whole hippocampal surfaces for all of the subjects were first rigidly aligned into a previously established template space, from which a population average was generated (Christensen et al. 2015, Csernansky et al. 2000). Perpendicular displacements were computed between corresponding vertices from this average to each subject. These displacements were then used as a measure of surface deformity for further analysis.

Statistical analysis on surfaces was performed using SurfStat in Matlab (Chung et al. 2010, Worsley et al. 2009) with modification for univariate and multivariate data. Multiple linear regression was used to investigate the association between in-vivo regional hippocampal surface deformation and postmortem neuropathologic markers of AD and TDP-43 pathology. Separate models were constructed to explore the association between surface deformity and regional amyloid-beta, phosphorylated tau, and TDP-43 burden. Age at death, sex, and time between MRI and death were included as covariates. A secondary analysis was done to include additional terms for coexisting disease processes including the other primary pathological diagnoses (PHF-tau, amyloid-beta, TDP-43) as well as hippocampal sclerosis, Lewy bodies, gross infarcts, atherosclerosis, arteriosclerosis, and CAA.

These analyses were first performed on the entire cohort (N=42), then repeated within the healthy controls (N=23) and combined clinical MCI+AD (N=19) separately. Finally, to examine robustness of the outcome, we performed the following experiments: In each experiment, we removed 4 subjects (approx. 10%) at random, computed the same surface relationships accounting for the same covariates as in the original analysis. We repeated this 10 times, with 4 different subjects removed each time.

A third multivariate analysis was performed excluding the 3 subjects with a clinical diagnosis of probable AD. Finally, a fourth analysis was done to examine the association between deformity and pathological diagnosis of AD using the NIA-Reagan Score.

In each analysis, a linear model was constructed for each vertex on the hippocampal surface map, with displacement (deformation) as the dependent variable and using neuropathology markers (TDP-43, amyloid-beta, and tau) and covariates as independent predictors (age at death, sex, time between MRI and death, and coexisting pathology including cerebrovascular disease, Lewy bodies, and hippocampal sclerosis). To control for multiple comparisons, Random Field Theory (RFT) (Robert J. Adler and Society for Industrial and Applied Mathematics. 2010; R. J. Adler and Hasofer 1976; Worsley 2005) was applied (within SurfStat). Since signals (i.e., hippocampal deformations) at neighboring vertices are necessarily correlated therefore may be spatially continuous (i.e., forming clusters), multiple comparison correction methods such as Bonferroni or false discovery rate (FDR) (Genovese et al. 2002) are not appropriate, as they only consider the peak of significance at individual vertices (Perneger 1998). RFT, however, considers both peaks and spatial extent of the signal by modeling the noise as Gaussian random fields (Chumbley and Friston 2009). This approach produced significant clusters of vertices at a desired family-wise error rate (FWER) (e.g., $p < 0.05$). Significant beta coefficients were visualized as color-maps superimposed on the population average hippocampal surface. To aid the visual interpretation of the patterns of relationships, template-based surface zones approximating the underlying CA1, subiculum, and combined CA2-4 and dentate gyrus hippocampal subfields, as previously described (Christensen et al. 2015, Csernansky et al. 2005, Wang et al. 2003), were utilized.

3. Results

3.1. Ante-mortem Population Characteristics

Demographic information including age at the time of MRI scan, age at death, sex, number of years of education is provided in Table 1. Total average left hippocampal volume (SD) was 2787 (438) mm³ and right 2877 (487) mm³. Overall, subjects had a spectrum of ante-mortem clinical diagnoses. Of the 42 subjects, 23 were determined to be cognitively normal (CN), 16 had a clinical diagnosis of mild cognitive impairment (MCI), and three had probable-AD. The three subjects with AD were impaired in memory by definition. Of the 16 subjects with MCI, nine were classified as amnesic (56%).

3.2. Distribution of Neuropathologies across Subjects

The presence of various neuropathologic markers upon autopsy is summarized in Table 2. Amyloid-beta was fairly evenly distributed across brain regions, while PHF-tau was more localized to the entorhinal cortex, hippocampus, and mesial temporal cortex. For TDP-43, the area most affected in subjects was the amygdala (42.5%), followed by hippocampal CA1 (31%), and dentate gyrus (14%). Of the 42 subjects, 25 received a post-mortem pathologic diagnosis of AD using modified NIA-Reagan scores (i.e., intermediate or high scale) (Bennett et al., 2006). The majority (88%) also had at least one non-AD neuropathology, including TDP-43 pathology (n=17: 6 localized to amygdala; 10 extension to hippocampus and/or entorhinal cortex; 1 extension to the neocortex), Lewy body diseases (9: 1 nigral predominant; 6 limbic type; 2 neocortical type), hippocampal sclerosis (3), and cerebral infarctions (7 gross only; 8 micro-chronic only; 8 both). Coexisting cerebrovascular pathologies were also common, including cerebral amyloid angiopathy (CAA, n=32: 23

mild; 8 moderate; 1 severe), cerebral atherosclerosis (32: 23 mild; 8 moderate; 1 severe), arteriolosclerosis (27: 17 mild; 9 moderate; 1 severe).

3.3. Relationship between Neuropathologic Burden and Hippocampal Surface Deformity

Figure 1 shows hippocampal surface maps representing the relationship between global PHF-tau, amyloid-beta, and TDP-43 levels and hippocampal surface deformity for all 42 subjects before and after accounting for coexisting pathology. Without accounting for coexisting pathology, higher global PHF-tau burden was associated with more inward deformity in surface zones approximating the CA1 and the subiculum, higher global amyloid-beta burden was associated with inward deformity in the surface zone approximating subiculum, and higher global TDP-43 levels were associated with inward deformity in the surface zone approximating CA1. Associations with each pathology demonstrate a distinct spatial pattern. After accounting for coexisting pathology, the relationship observed between higher PHF-tau burden and increased inward deformity in hippocampal surface zones approximating CA1 and subiculum remained. However, when covariates were included, the relationships previously observed for amyloid-beta and TDP-43 were no longer significant. In the experiments examining robustness of the outcome, nine out of the 10 experiments showed similar spatial patterns (not shown) as the original analysis.

Figure 2 left column shows hippocampal surface maps representing the relationship between global PHF-tau, amyloid-beta, and TDP-43 levels and hippocampal surface deformity in the 19 MCI + AD subjects before and after accounting for coexisting pathology. The patterns of association are similar to those obtained in the entire cohort. Without accounting for coexisting pathology, higher global PHF-tau burden were associated with more inward deformity in surface zones approximating the CA1 and subiculum, higher global amyloid-beta burden was associated with more inward deformity in the surface zone approximating the CA1, and higher global TDP-43 levels were associated with more inward deformity in surface zones approximating the CA1 and subiculum. We note that the associations demonstrate a distinct spatial pattern for each pathology. After accounting for coexisting pathology, all relationships were no longer significant (not shown).

Figure 2 right column shows hippocampal surface maps representing the relationship between global PHF-tau, amyloid-beta, and TDP-43 levels and hippocampal surface deformity in the 23 healthy control subjects before and after accounting for coexisting pathology. Without accounting for coexisting pathology, global amyloid-beta burden was not associated with hippocampal deformity, and higher PHF-tau and TDP-43 levels were associated with more inward deformity in the surface zone approximating the subiculum. However these associations appear to have only a minimum surface distribution. Higher global amyloid-beta burden was associated with inward deformity in the surface zone approximating the subiculum. After accounting for coexisting pathology, the relationship observed between higher TDP-43 levels and more inward deformity in the surface zone approximating the subiculum remained, and the relationship previously observed for PHF-tau was no longer significant (not shown).

4. Discussion

In this study of a community-based cohort of elderly adults, we explored whether three different underlying neuropathologic processes – PHF-tau, amyloid-beta, and TDP-43 – were associated with unique patterns of hippocampal deformation. When separately examined for the combined MCI + AD subjects vs. HC subjects, the associations were observed largely within the MCI + AD subjects. While several groups have previously explored the utility of hippocampal shape analysis in diagnosis of various dementia subtypes (Mak 2016 et al., Christensen et al. 2015, Khan et al. 2015, Chow et al. 2012), and one has examined the relationship between postmortem hippocampal atrophy and underlying neuropathologies (Dawe et al. 2011), our study is – to our knowledge – the first to examine association of different neuropathologies with *ante-mortem* hippocampal shape deformity using *neuropathologically-confirmed* cases.

In our study, higher levels of global PHF-tau burden were associated with increased shape deformation in surface zones approximating the CA1 and the subiculum regions of the hippocampus. This is consistent with prior imaging studies that have demonstrated early involvement of the hippocampal regions approximating the CA1 subfield in AD and MCI (La Joie et al. 2013, Tepest et al. 2008, Li et al. 2007, Scher et al. 2007, Wang et al. 2006 & 2003). While all of these studies relied on clinical rather than pathological classification of subjects, the fact that this relationship seems to hold when actual neuropathologic markers are taken into account yields credibility to the use of hippocampal subfield analysis as a biomarker for AD-specific neuropathology. That PHF-tau burden specifically correlated with selective atrophy in the surface zone approximating the CA1 region of the hippocampus further supports previous neuropathologic findings that show CA1 is one of the earliest regions affected by neurofibrillary tangle deposition (Braak & Braak, 1991; Schonheit et al. 2004, Fukutani et al. 2000). Furthermore, it has been shown that atrophy on MRI correlates with tau immunostaining burden (Whitwell et al. 2008). One must be cautious when making clinical inferences based solely on the presence of tau pathology and hippocampal atrophy, as these findings can also be present in a significant proportion of the “cognitively normal” elderly population (Lace et al. 2009, Arriagada et al. 1992b, Price et al. 1991). Nevertheless, in one recent structural MRI study, investigators noted a relationship between subjective cognitive decline – a self-reported perception of memory problems that is not picked up on during routine neuropsychologic testing – and selective atrophy of the hippocampal CA1 region (Perrotin et al. 2015). If hippocampal atrophy can indeed be identified on structural MRI in preclinical stages of disease years before the development of MCI, further exploration of this biomarker as a clinical screening tool may be warranted.

In regards to amyloid-beta, the relationship between neuropathologic disease burden and hippocampal subfield deformity was less clear. While increased inward deformity of the surface zone approximating the subiculum was related to increased amounts of global amyloid-beta burden, this relationship did not hold when covariates were accounted for. A recent study by Hsu et al combining the use of structural MRI and amyloid PET scanning found that the amyloid-beta positive group had a significantly smaller hippocampal tail, presubiculum, subiculum, and total hippocampal gray matter volume compared to the amyloid-beta negative group, while the groups did not differ in size of CA1, CA2/3, or CA4/

dentate gyrus (Hsu et al. 2015). While several other amyloid-PET imaging studies have shown relationships between amyloid-beta burden and various imaging markers of neurodegeneration (Chetelat et al. 2012, Becker et al. 2011, Dickerson et al. 2009, Storandt et al. 2009), none of these models included terms to account for coexisting pathology. Therefore, while studies that do not account for coexisting pathologies show that amyloid-beta influences neurodegeneration in the temporal region, our results suggest that it does so by mediating other neuropathologic pathways. This could explain studies that show amyloid-beta burden itself does not correlate well with brain atrophy (Josephs et al. 2008), and falls in line with neuropathologic studies which have shown that tau pathology has a stronger temporal and spatial correlation with neuronal loss than plaques (Musiek and Holtzman 2015, Gomez-Isla et al. 1997, Arriagada et al. 1992a), and that tau actually mediates the association of amyloid-beta with cognition (Bennett et al. 2004, Bennett et al. 2005, Yu et al. 2014). Several investigators have hypothesized that amyloid-beta may trigger a worsening of tau-related neurodegeneration (Wang et al. 2016, Musiek et al. 2015), while animal studies suggest that tau mediates the toxicity of amyloid-beta (Ittner et al. 2010). Further molecular studies would be needed to test these hypotheses.

For TDP-43, we observed a relationship between TDP-43 deposition and increased inward shape deformity in the surface zone approximating CA1, with a spatial distribution that was different from that of PHF-tau. However, this pattern did not hold when we accounted for coexisting pathologies. Further studies would be needed to confirm our preliminary evidence between TDP-43 deposition and unique patterns of neurodegeneration. Nevertheless, some studies have found an association between the presence of TDP-43 and hippocampal atrophy in subjects with coexisting AD pathology (Josephs et al. 2014a + 2014b, Josephs et al. 2015). This falls in line with neuropathologic studies that have indicated that the medial temporal lobe structures (including the hippocampus) are susceptible to TDP-43 inclusions in AD (James et al. 2016, Josephs et al. 2016, Josephs et al. 2014a + 2014b, Hu et al. 2008). Although their exact staging schemes differ, those studies strongly suggest that TDP-43 deposition in AD begins in the amygdala, spreads to the entorhinal cortex/hippocampus, and eventually includes other areas of the cortex (James et al. 2016, Josephs et al. 2016). Future structural MRI studies should include the amygdala to capture additional variation in patterns of AD- and TDP-related effects on neurodegeneration.

As mentioned above, hippocampal shape deformation showed unique patterns of association with PHF-tau, amyloid-beta, and TDP-43 within the MCI + AD subjects when not accounting for coexisting pathology. These patterns were similar to those obtained in the entire cohort, especially for PHF-tau. When visually compared with the healthy controls, the spatial distribution patterns were distinct and extended across much larger portions of the surfaces. These results suggest that the unique spatial patterns between hippocampal shape and AD and related pathologies can be potential biomarkers that could distinguish underlying disease pathologies in patients with a clinical diagnosis. Larger number of cases should be included in the future to confirm and validate these preliminary findings. Future studies can then develop approaches in which this type of information is used to select appropriate patients for clinical trials of specific disease-altering interventions. The findings on the healthy controls is intriguing, suggesting a preclinical disease process. While studies

have shown that some cognitively normal individuals carry AD and related pathologies, larger studies are needed to further validate our findings.

In a previously published study (Zarow et al. 2011), we used similar methods to compare hippocampal surface shape deformation between individuals with hippocampal sclerosis (HS) and AD. In that paper, we argued that clinical diagnosis of HS is rarely if ever, made, and in fact all HS cases from that study received a clinical diagnosis other than HS. In the current study, the amyloid-beta, PHF tau and TDP 43 pathologies were found in the three subjects with HS. Also, our analysis covariates for HS ratings, which were present (severe) or absent (possible or nonexistent). Therefore, our results demonstrate that antemortem MRI measures can relate to postmortem AD and related disorders (age related TDP 43 pathology) pathologies despite the presence of HS, which is well aligned with our overall hypothesis. Nonetheless more data with HS will be needed to determine whether HS with or without coexisting AD and TDP 43 pathologies also has specific shape changes.

Overall, our study had several important strengths. First, we relied on neuropathologically-confirmed cases, avoiding the need for making *a priori* assumptions regarding neuropathologic classification. This is essential because studies have shown that presently correlation between clinical symptoms and neuropathology subtypes could be poor (Mesulam et al. 2014). Second, the fact that the subjects were drawn from two community cohorts of older individuals who were enrolled as healthy participants (some of whom later converted to MCI/AD while others did not) may make the results more applicable to the general elderly population than they would be had subjects been drawn from memory clinics alone. Third, our method utilized structural MRI, which may be a more economical alternative to other imaging techniques such as amyloid- or tau-PET, as Medicare does not routinely reimburse these novel diagnostic studies in the work-up for mild cognitive impairment (Jacques et al. 2013). Finally, this work raises the possibility of prediction of multiple underlying neuropathologies using a single imaging study, which could be an advantage over PET methods which rely on multiple radioactive ligands.

However, our study also had some important limitations. First, the sample size was relatively small ($N = 42$), limiting our ability to detect subtle differences with enough power. For this reason, it would be essential to replicate these findings in larger study populations. Second, our ability to directly correlate neuroimaging with post-mortem neuropathologic data was limited by the fact that pathology was examined in sparse and relatively small areas of the brain, each covering 6-20 microns, whereas whole-brain/structure coverage would have been necessary to establish a true ante-mortem/post-mortem connection. Third, our study did not include results of clinical testing in the analysis. Consequently, it is difficult to draw conclusions regarding the clinical significance of hippocampal volume loss in respect to cognition. Additionally, hippocampal surface shape represented in this paper do not necessarily reflect atrophy specific to certain underlying subfields. For example, atrophy of the dentate gyrus may contribute to the surface shape deformation in the CA and subiculum areas as much of the dentate gyrus is not appreciated at the surface of the hippocampus. Finally, our study population had a mean age of about 88 years at the time of imaging, which is much older than the typical age of patients presenting to memory clinics. Therefore, the relationships we observed may be different in those populations. Further studies should be

done to validate our findings in larger study populations and to further characterize the relationship between TDP-43 burden and hippocampal shape.

Since our interpretation of the relationship between hippocampal shape and neuropathology burden was related to underlying subfields, variations on the anatomical definition of the subfields may influence the interpretation. As summarized in (Yushkevich et al., 2015), while there is good overlap among the 21 active hippocampal subfield segmentation protocols, differences exist as well. For example, while some protocols delineate each of the CA1-4, others combine them in different ways. Further, the boundary between the CA fields and their adjacent dentate gyrus and subiculum varies depending on the atlases used. Similar issues exist among automatic subfield methods (Mueller et al., 2018). Therefore, when localizing our observed relationships between hippocampal shape and neuropathology burdens to underlying subfields, caution should be exercised.

There is a complex set of correspondences between dementia-related syndromes and neuropathologies, which makes accurate antemortem diagnosis difficult. Recent studies have shown that patients often carry a mixture of neuropathologies. For example, significant numbers of clinical AD cases demonstrate admixtures of amyloid-beta and TDP-43 neuropathologies. Two decades of clinical trials of AD patients have failed to produce effective disease-modifying drugs, and inaccurate antemortem diagnosis has been implicated as a key contributing factor. The current study continues the work that addresses the unmet need for antemortem biomarkers that can identify patients with specific neuropathologies, so that future disease-altering drugs can be tested with more success. Larger numbers will be needed to further investigate the unique relationships between hippocampal deformation and specific pathologies. Amyloid, like PHF-tau are measured with high precision and there is work underway to more accurately define the quantity of TDP-43 pathology in each region. The success of disease-altering therapies depends largely on an early and specific diagnosis. Research presented in this paper could lead to tools that can be used in future clinical trials to identify the most appropriate patient populations for specific disease-altering interventions. The ability to create biomarkers based on structural MRI could be a powerful tool in differentiating between AD and non-AD pathologies at preclinical stages of disease. If and when effective disease-altering therapies are developed, our disease predicting biomarkers can be used to select the most appropriate therapies for the patient.

Acknowledgments:

We thank the participants of the Rush Memory and Aging Project and Religious Orders Study. The study was supported by NIH grants R01AG055121, P30AG10161, R01AG15819, R01AG17917, R01AG40039, K23AG40625, R01AG42210, R01EB020062, and UH2NS100599.

References:

- Adler RJ, Hasofer AM. Level-Crossings for Random Fields. *Ann Probab.* 1976;4(1):1–12.
- Adler RJ, Society for Industrial and Applied Mathematics. *The geometry of random fields Classics in applied mathematics* 62. SIAM ed. Philadelphia, Pa.: Society for Industrial and Applied Mathematics (SIAM, 3600 Market Street, Floor 6, Philadelphia, PA 19104); 2010.
- Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's

Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers & Dementia*. 2011 ;7(3):270–279.

Arriagada PV, Marzloff K and Hyman BT, 1992a Distribution of Alzheimer-type pathologic changes in nondemented elderly individuals matches the pattern in Alzheimer's disease. *Neurology* 42:1681–1688. [PubMed: 1307688]

Arriagada PV, Growdon JH, Hedley-Whyte ET and Hyman BT, 1992b Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. *Neurology* 42:631–639. [PubMed: 1549228]

Arvanitakis Z, Leurgans SE, Wang Z, Wilson RS, Bennett DA, Schneider JA, 2011 Cerebral amyloid angiopathy pathology and cognitive domains in older persons. *Ann. Neurol* 69, 320–327. [PubMed: 21387377]

Arvanitakis Z, Capuano AW, Leurgans SE, Buchman AS, Bennett DA, Schneider JA, 2017 The Relationship of Cerebral Vessel Pathology to Brain Microinfarcts. *Brain Pathol* 27(1), 77–85. [PubMed: 26844934]

Barnes LL, Schneider JA, Boyle PA, Bienias JL, Bennett DA, 2006 Memory complaints are related to Alzheimer disease pathology in older persons. *Neurology* 67(9):1581–5. [PubMed: 17101887]

Becker JA, Hedden T, Carmasin J, Maye J, Rentz DM, Putcha D, Fischl B, Greve DN, Marshall GA, Salloway S, Marks D, Buckner RL, Sperling RA, Johnson KA, 2011 Amyloid-beta associated cortical thinning in clinically normal elderly. *Ann. Neurol* 69, 1032–1042. [PubMed: 21437929]

Beg MF, Miller MI, Troune A, Younes L, 2005 Computing Large Deformation Metric Mappings via Geodesic Flows of Diffeomorphisms. *International Journal of Computer Vision* 61, 139.

Bennett DA, Wilson RS, Schneider JA, et al. Natural history of mild cognitive impairment in older persons. *Neurology*. 2002;59(2):198–205 [PubMed: 12136057]

Bennett DA, Schneider JA, Wilson RS, Bienias JL, Arnold SE. 2004 Neurofibrillary tangles mediate the association of amyloid load and with clinical Alzheimer's disease and level of cognitive function. *Arch Neurol* 61 (378-384).

Bennett DA, Schneider JA, Wilson RS, Bienias JL, Berry-Kravis E, Arnold SE. Amyloid mediates the association of apolipoprotein E e4 allele to cognitive function in older people. *J Neurol Neurosurg Psychiatry*. 2005 9;76(9):1194–9. [PubMed: 16107349]

Bennett DA, Schneider JA, Arvanitakis Z, Kelly JF, Aggarwal NT, Shah RC, Wilson RS, 2006 Neuropathology of older persons without cognitive impairment from two community-based studies. *Neurology*. 66(12):1837–44. [PubMed: 16801647]

Bennett DA, Schneider JA, Arvanitakis Z, Wilson RS, 2012a Overview and findings from the religious orders study. *Curr Alzheimer Res*. 9 628–645. [PubMed: 22471860]

Bennett DA, Schneider JA, Buchman AS, Barnes LL, Boyle PA, Wilson RS 2012b Overview and findings from the Rush Memory and Aging Project. *Curr Alzheimer Res*. 9, 646–663. [PubMed: 22471867]

Bennett DA, Wilson RS, Arvanitakis Z, Boyle PA, de Toledo-Morrell L, Schneider JA, 2013 Selected findings from the Religious Orders Study and Rush Memory and Aging Project. *Journal of Alzheimer's Disease* 33(Supp 1):S397–S403.

Boyle PA, Yu L, Nag S, Leurgans S, Wilson RS, Bennett DA, Schneider JA, 2015 Cerebral amyloid angiopathy and cognitive outcomes in community-based older persons. *Neurology* 85, 1930–1936. [PubMed: 26537052]

Buchman AS, Nag S, Leurgans SE, Miller J, VanderHorst V, Bennett DA, Schneider JA, 2017 Spinal Lewy body pathology in older adults without an antemortem diagnosis of Parkinson's disease. *Brain Pathol*.

Braak H, Braak E, 1991 Neuropathological staging of Alzheimer-related changes. *Acta Neuropathol*. 82(4):239–59. [PubMed: 1759558]

Chang XL, Tan MS, Tan L, Yu JT, 2016 The role of TDP-43 in Alzheimer's Disease. *Mol Neurobiol* 53(5):3349–59. [PubMed: 26081142]

Chetelat G, Villemagne VL, Villain N, Jones G, Ellis KA, Ames D, Martins RN, Masters CL, and Rowe CC, AIBL Research Group, 2012 Accelerated cortical atrophy in cognitively normal elderly with high b-amyloid deposition. *Neurology* 78, 477–484. [PubMed: 22302548]

- Chow N, Aarsland D, Honarpisheh H, Beyer MK, Somme JH, Elashoff D, Rongve A, Tysnes OB, Thompson PM, Apostolova LG, 2012 Comparing hippo-campal atrophy in Alzheimer's dementia and dementia with Lewy bodies. *Dement Geriatr Cogn Disord* 34:44e50. [PubMed: 22922563]
- Christensen A, Alpert K, Rogalski E, Cobia D, Rao J, Beg M, Weintraub S, Mesulam M, Wang L, 2015 Hippocampal subfield surface deformity in non-semantic primary progressive aphasia. *Alzheimers Dement (Amst)* 1(1):14–23. [PubMed: 25893207]
- Chumbley JR, Friston KJ. False discovery rate revisited: FDR and topological inference using Gaussian random fields. *Neuroimage*. 2009;44(1):62–70. [PubMed: 18603449]
- Chung MK, Worsley KJ, Nacewicz BM, Dalton KM, Davidson RF, 2010 General multivariate linear modeling of surface shape using SurfStat. *Neuroimage* 53(2): 491–505. [PubMed: 20620211]
- Clark CM, Pontecorvo MJ, Beach TG, Bedell BJ, Coleman RE, Doraiswamy PM, Fleisher AS, Reiman EM, Sabbagh MN, Sadowsky CH, Schneider JA, Arora A, Carpenter AP, Flitter ML, Joshi AD, Krautkramer MJ, Lu M, Mintun MA, Skovronsky DM, AV-45-A16 Study Group, 2012 Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid- β plaques: a prospective cohort study. *Lancet Neurol* 11: 669–78 [PubMed: 22749065]
- Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Asse. 1997 18(4 Suppl):S1–2.
- Csernansky JG, Wang L, Joshi S, Miller AB, Gado M, Kido D, McKeel D, Morris JC, Miller MI, 2000 Early DAT is distinguished from aging by high-dimensional mapping of the hippocampus. *Neurology* 55: 1636–43. [PubMed: 11113216]
- Csernansky JG, Wang L, Joshi SC, Ratnanather JT, Miller MI, 2004 Computational anatomy and neuropsychiatric disease: probabilistic assessment of variation and statistical inference of group difference, hemispheric asymmetry, and time-dependent change. *Neuroimage* 23 Suppl 1, S56–68. [PubMed: 15501101]
- Csernansky JG, Wang L, Swank J, Miller JP, Gado M, McKeel D, Miller MI, Morris JC, 2005 Preclinical detection of Alzheimer's disease: hippocampal shape and volume predict dementia onset in the elderly. *NeuroImage* 25(3):783–92. [PubMed: 15808979]
- Davatzikos C, Resnick SM, Wu X, Pampi P, Clark CM, 2008 Individual patient diagnosis of AD and FTD via high-dimensional pattern classification of MRI. *Neuroimage* 41(4):1220–7. [PubMed: 18474436]
- Dawe RJ, Bennett DA, Schneider JA, Leurgans SE, Kotrotsou A, Boyle PA, Arfanakis K, 2011 Neuropathologic correlates of hippocampal atrophy in the elderly: a clinical, pathologic, postmortem MRI study. *PLoS One* 6, e26286. [PubMed: 22043314]
- De Flores R, La Joie R, Chetelat G, 2015 Structural imaging of hippocampal subfields in healthy aging and Alzheimer's disease. *Neuroscience* 309:29–50. [PubMed: 26306871]
- Dickerson BC, Bakkour A, Salat DH, Feczko E, Pacheco J, Greve DN, Grodstein F, Wright CI, Blacker D, Rosas HD, Sperling RA, Atri A, Growdon JH, Hyman BT, Morris JC, Fischl B, Buckner RL, 2009 The cortical signature of Alzheimer's disease: regionally specific cortical thinning relates to symptom severity in very mild to mild AD dementia and is detectable in asymptomatic amyloid-positive individuals. *Cereb. Cortex* 19, 497–510. [PubMed: 18632739]
- Du AT, Schuff N, Kramer JK, Rosen HJ, Gorno-Tempini ML, Rankin K, Miller BL, Weiner MW, 2007 Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia. *Brain* 130(4):1159–66. [PubMed: 17353226]
- Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C, van der Kouwe A, Kilianny R, Kennedy D, Klaveness S, Montillo A, Makris N, Rosen B, Dale AM, 2002 Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. *Neuron* 33, 341–355. [PubMed: 11832223]
- Frisoni GB, Fox NC, Jack CR, Scheltens P, Thompson PM, 2010 The clinical use of structural MRI in Alzheimer disease. *Nat Rev Neurol* 6:67–77. [PubMed: 20139996]
- Fukitani Y, Cairns NJ, Shiozawa M, Sasaki K, Sudo S, Isaki K, and Lantos PL, 2000 Neuronal loss and neurofibrillary degeneration in the hippocampal cortex in late-onset sporadic Alzheimer's disease. *Psychiatry Clin Neurosci* 54(5):523–9. [PubMed: 11043800]

- Genovese CR, Lazar NA, Nichols T. Thresholding of statistical maps in functional neuroimaging using the false discovery rate. *Neuroimage*. 2002;15(4):870–878. [PubMed: 11906227]
- Gómez-Isla T, Hollister R, West H, Mui S, Growdon JH, Petersen RC, Parisi JE, Hyman BT, 1997 Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease. *Ann. Neurol* 41: 17–24. [PubMed: 9005861]
- Hsu PJ, Shou H, Benzinger T, Marcus D, Durbin T, Morris JC, Sheline YI, 2015 Amyloid burden in cognitively normal elderly is associated with preferential hippocampal subfield volume loss. *J Alzheimers Dis*. 45(1):27–33. [PubMed: 25428255]
- Hu WT, Josephs KA, Knopman DS, Boeve BF, Dickson DW, Petersen RC, Parisi JE, 2008 Temporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease. *Acta Neuropathol*. 116(2):215–20. [PubMed: 18592255]
- Hurd MD, Martorell P, Delavande A, Mullen KJ, Langa KM, 2013 Monetary costs of dementia in the United States. *N Engl J Med*. 368(14):1326–34. [PubMed: 23550670]
- Ittner LM, Ke YD, Delerue F, Bi M, Gladbach A, van Eersel J, Wolfing H, Chieng BC, Christie MJ, Napier IA, Eckert A, 2010 Dendritic Function of Tau Mediates Amyloid- β Toxicity in Alzheimer's Disease Mouse Models. *Cell* 142(3):387–397. [PubMed: 20655099]
- Jacques L, Jensen T, Rollins J et al., 2013, 9 27 Decision Memo for Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease (CAG-00431N). Centers for Medicare and Medicaid Services. Available at: <https://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=265> Accessed December 20, 2016.
- James BD, Wilson RS, Boyle PA, Trojanowski JQ, Bennett DA, Schneider JA, 2016 TDP-43 stage, mixed pathologies, and clinical Alzheimer's-type dementia. *Brain* 139:2983–2993. [PubMed: 27694152]
- Josephs KA, Whitwell JL, Ahmed Z, Shiung MM, Weigand SD, Knopman DS, Boeve BF, Parisi JE, Petersen RC, Dickson DW, Jack CR, Jr, 2008 Beta amyloid burden is not associated with rates of brain atrophy. *Ann Neurol* 63(2):204–12 [PubMed: 17894374]
- Josephs KA, Whitwell JL, Weigand SD, Murray ME, Tosakulwong N, Liesinger AM, Petrucelli L, Senjem ML, Knopman DS, Boeve BF, Ivnik RJ, Smith GE, Jack CR, Jr, Parisi JE, Petersen RC, Dickson DW, 2014 TDP-43 is a key player in the clinical features associated with Alzheimer's disease. *Acta Neuropathol* 127(6):811–24. [PubMed: 24659241]
- Josephs KA, Murray ME, Whitwell JL, Parisi JE, Petrucelli L, Jack CR, Petersen RC, Dickson DW, 2014 Staging TDP-43 pathology in Alzheimer's disease. *Acta Neuropathol* 127:441–450. [PubMed: 24240737]
- Josephs KA, Whitwell JL, Tosakulwong N, Weigand SD, Murray ME, Liesinger AM, Petrucelli L, Senjem ML, Ivnik RJ, Parisi JE, Petersen RC, Dickson DW, 2015 TDP-43 and pathological subtype of Alzheimer's disease impact clinical features. *Ann Neurol* 78(5):697–709. [PubMed: 26224156]
- Josephs KA, Murray ME, Whitwell JL, Tosakulwong N, Weigand SD, Petrucelli L, Liesinger AM, Petersen RC, Parisi JE, Dickson DW, 2016 Updated TDP-43 in Alzheimer's disease staging scheme. *Acta Neuropathol* 131:571–585. [PubMed: 26810071]
- Kantarci K, Ferman TJ, Boeve BF, Weigand SD, Przybelski S, Vemuri P, Murray ME, Senjem ML, Smith GE, Knopman DS, Petersen RC, Jack CR, Jr, Parisi JE, Dickson DW, 2012 Focal atrophy on MRI and neuro-pathologic classification of dementia with Lewy bodies. *Neurology* 79(6), 553–560. [PubMed: 22843258]
- Kapasi A, DeCarli C, Schneider JA, 2017 Impact of multiple pathologies on the threshold for clinically overt dementia. *Acta Neuropathologica* 134, 171–186. [PubMed: 28488154]
- Karageorgiou E, Miller BL 2014 Frontotemporal lobar degeneration: a clinical approach. *Semin Neurol*. 34(2):189–201. [PubMed: 24963678]
- Khan A, Wang L, Beg MF. 2008 Freesurfer-initiated fully-automated subcortical brain segmentation in MRI using large deformation diffeomorphic metric mapping. *NeuroImage* 41(3): 735–746. [PubMed: 18455931]
- Khan W, Westman E, Jones N, Wahlund LO, Mecocci P, Vellas B, Tsolaki M, Kloszewska I, Soininen H, Spenger C, Lovestone S, Muehlboeck JS, Simmons A; AddNeuroMed consortium and for the Alzheimer's Disease Neuroimaging Initiative, 2015 Automated hippocampal subfield measures as

predictors of conversion from mild cognitive impairment to Alzheimer's disease in two independent cohorts. *Brain Topogr* 28(5):746–59. [PubMed: 25370484]

- Kim HJ, Ye BS, Yoon CW, Noh Y, Kim GH, Cho H, Jeon S, Lee JM, Kim JH, Seong JK, Kim CH, Choe YS, Lee KHm, Kin ST, Kim JS, Park SE, Kim JH, Chin J, Cho J, Kim C, Lee JH, Weinger MW, Na DL, Seo SW, 2014 Cortical thickness and hippocampal shape in pure vascular mild cognitive impairment and dementia of subcortical type. *Eur J Neurol* 21(5):744–51. [PubMed: 24495089]
- Knopman DS, Dekosky ST, Cummings JL, Chui H, Corey-Bloom J, Relkin N, Small GW, Miller B, Stevens JC, 2001 Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. *Neurology* 56(9): 1143–43. [PubMed: 11342678]
- Kotrotsou A, Schneider JA, Bennett DA, Leurgans SE, Dawe RJ, Boyle PA, Golak T, Arfanakis K, 2015 Neuropathologic correlates of regional brain volumes in a community cohort of older adults. *Neurobiology of Aging* 36: 2798–2805. [PubMed: 26195068]
- Kovacs GG, Milenkovic I, Wohrer A, Hoftberger R, Gelpi E, Haberler C, Honigschnabl S, Reiner-Concin A, Heinzl H, Jungwirth S, Krampla W, Fischer P, Budka H, 2013 Non-Alzheimer neurodegenerative pathologies and their combinations are more frequent than commonly believed in the elderly brain: a community-based autopsy series. *Acta Neuropathol* 126(3):365–384. [PubMed: 23900711]
- Lace G, Savva GM, Forster G, de Silva R, Brayne C, Matthews FE, Barclay JJ, Dakin L, Ince PG, Wharton SB ;MRC-CFAS, 2009 Hippocampal tau pathology is related to neuroanatomical connections: an ageing population-based study. *Brain* 132(5): 1324–1334. [PubMed: 19321462]
- La Joie R, Perrotin A, de La Sayette V, Egret S, Doeuvre L, Belliard S, Eustache F, Desgranges B, Chetelat G, 2013 Hippocampal subfield volumetry in mild cognitive impairment, Alzheimer's disease, and semantic dementia. *Neuroimage Clin* 3:155–62. [PubMed: 24179859]
- Li S, Shi F, Pu F, Li X, Jiang T, Xie S, Wang Y, 2007 Hippocampal Shape Analysis of Alzheimer Disease Based on Machine LearningMethods. *Am J Neuroradiol* 28: 1339–1345. [PubMed: 17698538]
- Li X, Li D, Li Q, Li Y, Li K, Li S, Han Y, 2016 Hippocampal subfield volumetry in patients with subcortical vascular mild cognitive impairment. *Sci Rep* 6:20873. [PubMed: 26876151]
- Mak E, Su L, Williams GB, Watson R, Firbank M, Blamire A, O'Brien J, 2016 Differential Atrophy of Hippocampal Subfields: A comparative study of dementia with Lewy Bodies and Alzheimer Disease. *American Journal of Geriatric Psychiatry* 24(2):136–143. [PubMed: 26324541]
- McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical-Diagnosis of Alzheimers-Disease - Report of the Nincds-Adrda Work Group under the Auspices of Department-of-Health-and-Human-Services Task-Force on Alzheimers-Disease. *Neurology*. 1984;34(7):939–944. [PubMed: 6610841]
- McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. *Alzheimers & Dementia*. 2011;7(3): 263–269.
- Mesulam MM, Weintraub S, Rogalski EJ, Wieneke C, Geula C, Bigio EH, 2014 Asymmetry and heterogeneity of Alzheimer's and frontotemporal pathology in primary progressive aphasia. *Brain* 137:1176–1192. [PubMed: 24574501]
- Mueller SG, Schuff N, Yaffe K, Madison C, Miller B, Weiner MW, 2010 Hippocampal atrophy patterns in mild cognitive impairment and Alzheimer's disease. *Hum Brain Mapp* 31 (9):1339–1347. [PubMed: 20839293]
- Mueller SG, Yushkevich PA, Das S, Wang L, Van Leemput K, Iglesias JE, Alpert K, Mezher A, Ng P, Paz K, Weiner MW, 2018 Systematic comparison of different techniques to measure hippocampal subfield volumes in ADNI2. *NeuroImage: Clinical* 17, 1006–1018. [PubMed: 29527502]
- Musiek ES and Holtzman DM, 2015 Three dimensions of the amyloid hypothesis: time, space, and 'wingmen'. *Nat Neurosci* 18(6):800–806. [PubMed: 26007213]
- Ossenkoppele R, Jansen WJ, Rabinovici GD, et al., 2015 Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis. *JAMA* 313: 1939–49. [PubMed: 25988463]

- Perneger TV. What's wrong with Bonferroni adjustments. *BMJ*. 1998;316(7139):1236–1238. [PubMed: 9553006]
- Perrotin A, de Flores R, Lamberton F, Poisnel G, La Joie R, de la Sayette V, Mezenge F, Tomadesso C, Landeau B, Desgranges B, Chetelat G, 2015 Hippocampal subfield volumetry and 3D surface mapping in subjective cognitive decline. *J Alzheimers Dis* 2015 9 24;48 Suppl 1:S141–50. [PubMed: 26402076]
- Price JL, Davis PB, Morris JC & White DL, 1991 The distribution of tangles, plaques and related immunohistochemical markers in healthy aging and Alzheimer's disease. *Neurobiol. Aging* 12:295–312. [PubMed: 1961359]
- Raman MR, Preboske GM, Przybelski SA, Gunter JL, Senjem ML, Vemuri P, Murphy MC, Murray ME, Boeve BF, Knopman DS, Petersen RC, Parisi JE, Dickson DW, Jack CR, Jr. Kantarci K, 2014 Antemortem MRI findings associated with microinfarcts at autopsy. *Neurology* 82, 1951e1958. [PubMed: 24793188]
- Rohrer JD, Rosen HJ, 2013 Neuroimaging in frontotemporal dementia. *Int Rev Psychiatry* 25(2):221–229. [PubMed: 23611351]
- Scheltens P, Blennow K, Breteler MMB, de Strooper B, Frisoni GB, Salloway S, Van der Flier WM, 2016 Alzheimer's disease. *The Lancet* 388(10043):505–517
- Scher AI, Xu Y, Korf ESC, White LR, Scheltens, 2007 Hippocampal shape analysis in Alzheimer's disease: A population-based study. *Neuroimage* 36: 8–18 [PubMed: 17434756]
- Schneider JA, Wilson RS, Bienias JL, Evans DA, Bennett DA, 2004 Cerebral infarctions and the likelihood of dementia from Alzheimer's disease pathology. *Neurology* 62: 1148–1156. [PubMed: 15079015]
- Schneider JA, Arvanitakis Z, Bang W, Bennett DA, 2007a Mixed brain pathologies account for most dementia cases in community-dwelling older persons. *Neurology* 69(24):2197–204 [PubMed: 17568013]
- Schneider JA, Boyle PA, Arvanitakis Z, Bienias JL, Bennett DA 2007b Subcortical infarcts, Alzheimer's disease pathology, and memory function in older persons. *Ann. Neur* 62(1):59–66.
- Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. 2009 The neuropathology of probable Alzheimer disease and mild cognitive impairment. *Ann. Neurol* 66(2):200–208. [PubMed: 19743450]
- Schneider JA, Arvanitakis Z, Yu L, Boyle PA, Leurgans SE, Bennett DA, 2012 Cognitive impairment, decline, and fluctuations in older community-dwelling persons with Lewy bodies. *Brain* 135:3005–3014. [PubMed: 23065790]
- Schönheit B, Zarski R, Ohn TG, 2004 Spatial and temporal relationships between plaques and tangles in Alzheimer-pathology. *Neurobiology of Aging* 25:697–711. [PubMed: 15165691]
- Storandt M, Mintun MA, Head D, and Morris JC, 2009 Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition. *Arch. Neurol* 66(12):1476–1481. [PubMed: 20008651]
- Stoub TR, Bulgakova M, Leurgans S, Bennett DA, Fleischman D, Turner DA, deToledo-Morrell L, 2005 MRI Predictors of risk of incident Alzheimer disease: a longitudinal study. *Neurology* 64(9): 1520–4. [PubMed: 15883311]
- Taylor JE and Worsley KJ, 2007 Detecting sparse signal in random fields, with an application to brain mapping. *Journal of the American Statistical Association* 102(479): 913–928.
- Tepes R, Wang L, Csernansky JG, Neubert P, Heun R, Scheef L, Jessen F, 2008 Hippocampal surface analysis in subjective memory impairment, mild cognitive impairment, and Alzheimer's dementia. *Dement Geriatr Cogn Disord* 26:323–329. [PubMed: 18841017]
- Tinetti ME, McAvay GJ, Murphy TE, Gross CP, Lin H, Allore HG, 2012 Contribution of individual diseases to death in older adults with multiple diseases. *J Am Geriatr Soc* 60(8):1448–56 [PubMed: 22734792]
- Thaker AA, Weinberg B, Dillon WP, Hess CP, Cabral HJ, Fleischman DA, Leurgans SE, Bennett DA, Hyman BT, Albert MS, Killiany RJ, Fischl B, Dale AM, Desikan RS. Entorhinal cortex: antemortem cortical thickness and post-mortem neurofibrillary tangle and amyloid pathology. *American Journal of Neuroradiology*. 2017;38:961–965.

- Toledo JB, Cairns NJ, Da X, Chen K, Carter D, Fleisher A, Householder E, Ayutyanont N, Roontiva A, Bauer RJ, Eisen P, Shaw LM, Davatzikos C, Weinger MW, Reiman EM, Morris JC, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative (ADNI), 2013 Clinical and multimodal biomarker correlates of ADNI neuropathological findings. *Acta Neuropathologica Communications* 1:65. [PubMed: 24252435]
- Vemuri P, Simon G, Kantarci K, Whitwell JL, Senjem ML, Przybelski SA, Gunter JL, Josephs KA, Knopman DS, Boeve BF, Ferman TJ, Dickson DW, Parisi JE, Petersen RC, Jack CR, Jr, 2011 Antemortem differential diagnosis of dementia pathology using structural MRI: Differential-STAND. *Neuroimage* 55:522–531. [PubMed: 21195775]
- Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC, 2015 Tau imaging: early progress and future directions. *Lancet Neurol* 14:114–24. [PubMed: 25496902]
- Wang L, Swank JS, Glick IE, Gado MH, Miller MI, Morris JC, Csernansky JG, 2003 Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging. *Neuroimage* 20: 667–682. [PubMed: 14568443]
- Wang L, Miller JP, Gado MH, McKeel DW, Rothermich M, Miller MI, Morris JC, Csernansky JG, 2006 Abnormalities of hippocampal surface structure in very mild dementia of the Alzheimer type. *Neuroimage* 30:52–60. [PubMed: 16243546]
- Wang L, Khan A, Csernansky JG, Fischl B, Miller MI, Morris JC, Beg MF, 2009 Fully-automated, multistage hippocampus mapping in very mild Alzheimer Disease. *Hippocampus* 19:541–548. [PubMed: 19405129]
- Wang L, Benzinger TL, Su Y, Christensen J, Friedrichsen K, Aldea P, McConathy J, Cairns NJ, Fagan AM, Morris JC, Ances BM, 2016 Evaluation of tau imaging in staging Alzheimer disease and revealing interactions between beta-amyloid and tauopathy. *JAMA Neurology* 73(9):1070–1077. [PubMed: 27454922]
- Whitwell JL, Josephs KA, Murray ME, Kantarci K, Przybelski SA, Weigand SD, Vemuri P, Senjem ML, Parisi JE, Knopman DS, Boeve BF, Petersen RC, Dickson DW, Jack CR, Jr, 2008 MRI correlates of neurofibrillary tangle pathology at autopsy: a voxel-based morphometry study. *Neurology* 71:743–49. [PubMed: 18765650]
- Wilson AC, Dugger BN, Dickson DW, Wang DS, 2011 TDP in aging and Alzheimer's disease – a review. *Int J Clin Exp Pathol* 4(2):147–155. [PubMed: 21326809]
- Wilson RS, Yu L, Trojanowski JQ, Chen EY, Boyle PA, Bennett DA, Schneider JA, 2013 TDP-43 Pathology, Cognitive Decline, and Dementia in Old Age. *Jama Neurol* 70(11), 1418–1424. [PubMed: 24080705]
- Worsley KJ. An improved theoretical P value for SPMs based on discrete local maxima. *Neuroimage*. 2005;28(4):1056–1062. [PubMed: 16125975]
- Worsley K, Taylor J, Carbonell F, et al. SurfStat: A Matlab toolbox for the statistical analysis of univariate and multivariate surface and volumetric data using linear mixed effects models and random field theory. Paper presented at: Organization for Human Brain Mapping 2009; San Francisco, CA.
- Yu L, Boyle PA, Leurgans S, Schneider JA, Bennett DA. Disentangling the effects of age and APOE on neuropathology and late life cognitive decline. *Neurobiol Aging*. 2014 4;35(4):819–26. [PubMed: 24199961]
- Yushkevich PA, Amaral RS, Augustinack JC, Bender AR, Bernstein JD, Boccardi M, Bocchetta M, Burggren AC, Carr VA, Chakravarty MM, Chetelat G, Daugherty AM, Davachi L, Ding SL, Ekstrom A, Geerlings MI, Hassan A, Huang Y, Iglesias JE, La Joie R, Kerchner GA, LaRocque KF, Libby LA, Malykhin N, Mueller SG, Olsen RK, Palombo DJ, Parekh MB, Pluta JB, Preston AR, Pruessner JC, Ranganath C, Raz N, Schlichting ML, Schoemaker D, Singh S, Stark CE, Suthana N, Tompary A, Turowski MM, Van Leemput K, Wagner AD, Wang L, Winterburn JL, Wisse LE, Yassa MA, Zeineh MM, for the Hippocampal Subfields, G., 2015 Quantitative comparison of 21 protocols for labeling hippocampal subfields and parahippocampal subregions in in vivo MRI: Towards a harmonized segmentation protocol. *Neuroimage*.
- Zarow C, Wang L, Chui HC, Weiner MW, Csernansky JG, 2011 MRI shows more severe hippocampal atrophy and shape deformation in hippocampal sclerosis than in Alzheimer's disease. *Int J Alzheimers Dis*.

Highlights:

- Higher tau deposition correlates with inward hippocampal deformity on in-vivo MRI
- Patterns observed for TDP-43 and amyloid not significant in multivariate model
- Hippocampal CA1 deformity proposed as biomarker for preclinical AD

Figure 1. Visualization of the relationship between global immunohistochemical pathology-burden and hippocampal surface deformity for PHF-tau (A), amyloid-beta (B), and TDP-43 (C) for all subjects.

Left panels show results for univariate analysis, while right panels show results after accounting for age, sex and time between MRI and death, and coexisting pathology including cerebrovascular disease, Lewy bodies, and hippocampal sclerosis. Maps are thresholded to show only clusters which remained significant after correction for multiple comparisons using random field theory (RFT) with a family-wise error rate (FWER) < 0.05. Empty panels indicate non-significance. Color-maps represent standardized beta-coefficients

at each vertex for a linear model using deformity as the dependent variable and pathology score as the predictor. Darker colors represent inward surface deformation (localized volume loss). L = left hippocampus, R = right hippocampus, CA = cornu ammonis, sub = subiculum, DG = dentate gyrus. “Top View” represents surface viewed from above, with head of hippocampus pointing downward, while “Bottom View” represents surface as viewed from below, with head of hippocampus pointing upward.

Figure 2. Visualization of the relationship between global immunohistochemical pathology-burden and hippocampal surface deformity for PHF-tau (A), amyloid-beta (B), and TDP-43 (C) for the MCI+AD (left column) and HC (right column) subjects.

Panels show results for univariate analysis. Maps are thresholded to show only clusters which remained significant after correction for multiple comparisons using random field theory (RFT) with a family-wise error rate (FWER) < 0.05. Empty panels indicate non-significance. Color-maps represent standardized beta-coefficients at each vertex for a linear model using deformity as the dependent variable and pathology score as the predictor. Darker colors represent inward surface deformation (localized volume loss). L = left

hippocampus, R = right hippocampus, CA = cornu ammonis, sub = subiculum, DG = dentate gyrus. “Top View” represents surface viewed from above, with head of hippocampus pointing downward, while “Bottom View” represents surface as viewed from below, with head of hippocampus pointing upward.

Author Manuscript

Author Manuscript

Author Manuscript

Author Manuscript

Table 1.
Demographic Information.

Of the 19 MCI+AD participants, 12 (63%) were classified as being impaired in the memory domain. Within the MCI group alone 9/16 were classified as amnesic (56%).

Characteristics	Value
N	42
Male, n (%)	17 (40%)
Age at visit (mean, sd) [range, median]	87.6, 5.0 [77.1 - 100.2, 87.1] years
Age at death (mean, sd) [range, median]	90.4, 5.0 [79.5 - 102.6, 89.5] years
Time from last MRI to death (mean, sd) [range]	2.7, 1.2 [0.17 - 4.8, 2.6] years
Years educ (mean, sd) [range, median]	15.0, 3.3 [8.0 - 22.0, 15.0] years
Ante-mortem clinical diagnosis, n (%)	
NL	23 (54.7%)
MCI	16 (38.1%)
AD	3 (7.2%)

NL = normal cognition, MCI = Mild Cognitive Impairment, AD = probable AD-dementia

Table 2.
Summary of neuropathologic findings at autopsy.

Global amyloid-beta and tangle scores were computed by taking a mean across 8 regions (hippocampus, entorhinal cortex, midfrontal gyrus, inferior temporal, anterior gyrus, calcarine cortex, cingulate region, superior frontal gyrus).

Characteristics	N(%)
<i>Tau</i>	
global	42 (100%)
hippocampal	42 (100%)
<i>Amyloid-beta</i>	
global	38 (90.4%)
hippocampal	26 (64.3%)
<i>TDP-43</i>	
global	18 (42.8%)
hippocampal	13 (30.9%)
<i>Lewy bodies</i>	8 (19.0%)
<i>Hippocampal sclerosis</i>	3 (7.1%)
<i>Cerebral amyloid angiopathy</i>	32 (76%)
<i>Atherosclerosis</i>	
none	10 (23.8%)
mild	23 (54.8%)
moderate	8 (19.0%)
severe	1 (2.4%)
<i>Arteriolosclerosis</i>	
none	15 (35.7%)
mild	17 (40.5%)
moderate	9 (21.4%)
severe	1 (2.4%)
<i>Chronic infarcts (any size)</i>	
none	19 (45.2%)
one	12 (28.6%)
multi-infarct	11 (26.2%)